Pinatuzumab vedotin

Pinatuzumab vedotin is an antibody-drug conjugate designed for the treatment of cancer. It is composed of an antibody (pinatuzumab) linked to a cytotoxic agent (vedotin). The antibody targets CD22, a protein commonly found on B cells, and delivers the cytotoxic agent to these cells, causing their death.

Development

Pinatuzumab vedotin was developed by Genentech, a member of the Roche Group. It was granted orphan drug status by the Food and Drug Administration (FDA) in 2014 for the treatment of diffuse large B-cell lymphoma (DLBCL) and indolent non-Hodgkin lymphoma (iNHL).

Clinical trials

Several clinical trials have been conducted to evaluate the safety and efficacy of pinatuzumab vedotin. In a phase II study, the drug showed promising results in patients with relapsed or refractory DLBCL and iNHL. However, further development of the drug was discontinued in 2016 due to unfavorable risk-benefit profile.

Mechanism of action

Pinatuzumab vedotin works by binding to CD22 on the surface of B cells. Once bound, the drug is internalized and the cytotoxic agent is released, causing cell death. The specificity of the antibody for CD22 allows for targeted delivery of the cytotoxic agent, minimizing damage to healthy cells.

Side effects

Common side effects of pinatuzumab vedotin include fatigue, nausea, diarrhea, and fever. Serious side effects can include neutropenia, thrombocytopenia, and anemia.

See also

• Antibody-drug conjugate
• CD22
• Diffuse large B-cell lymphoma
• Indolent non-Hodgkin lymphoma

Pinatuzumab vedotin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia